Royalty Pharma Raises $2.2 Billion in Largest IPO of the Year to Date

Paul, Weiss advised General Atlantic in its investment in Royalty Pharma PLC, a leading funder of innovation across the biopharmaceutical industry, and Royalty Pharma’s subsequent initial public offering. The offering raised $2.2 billion, the largest IPO of the year to date and the second-largest pharmaceutical listing ever. Royalty Pharma priced its IPO at $28.00 per Class A ordinary share, at the top end of its target price range, and upsized the deal.

The Paul, Weiss team includes, among others, corporate partners Matthew Abbott, Conrad van Loggerenberg, Christopher Cummings, Amran Hussein, Marco Masotti, Manuel Frey, and Robert Zochowski and counsel Bruce Gruder, Philip Heimowitz, Christian Kurtz and Scott Grader; tax partners Patrick Karsnitz, David Mayo and Lindsay Parks; intellectual property partner Charles Googe; litigation partner Walter Ricciardi; and antitrust counsel Marta Kelly.